BETA
Your AI-Trained Oncology Knowledge Connection!
Newly Approved Agent for Diffuse Midline Glioma Shows Tolerable AE Profile
Dordaviprone was recommended at a dose of 625 mg orally once weekly for adults, and the recommended dosage is based on body weight for pediatric patients.
Further Research on Anti-CD38 mAbs Warranted in Multiple Myeloma
A systematic review of 8 randomized trials showed that anti-CD38 monoclonal antibodies did not improve overall survival in high-risk subgroups.
Tuspetinib Exhibits Enhanced Efficacy in Diverse Newly Diagnosed AML Group
No minimal residual disease-negativity was observed with tuspetinib in patients with AML, including in a patient with more than 7 months of follow-up data.
Carfilzomib Regimens Improve MRD Outcomes in Older, Fit NDMM Population
Phase 3 findings may contribute to the selection of triplet or quadruplet therapies in newly diagnosed multiple myeloma via frailty-based assessments.
Nirogacestat Receives European Approval for Treatment of Desmoid Tumors
The EC decision is based on phase 3 DeFi trial results, in which nirogacestat met the primary end point of PFS in patients with progressing desmoid tumors.
Novel Vaccine Shows Early Responses in Pancreatic Cancer and CRC
Phase 1 data may support continued research of amphiphile lymph node-targeted immunotherapy in solid tumors.
Dorvdaiprone Exhibits Durability in H3 K27M-Mutated Diffuse Midline Glioma
Extended follow-up for individuals with H3 K27M-mutated diffuse midline glioma may help explain the duration of response across patient subgroups.
ctDNA Test is Predictive of Adjuvant Atezolizumab Benefit in MIBC
Patients with muscle-invasive bladder cancer with a positive Signatera test displayed a significant improvement in disease-free and overall survival.
Beyond the Tumor: Addressing Body Image in Oncology
Daniel C. McFarland, DO, and Michelle Fingeret, PhD, discuss the issue of body image in patients with cancer.
Robotic Surgery Exhibits Benefit in Select Colorectal Cancer Procedures
Outcomes favoring robotic surgery for CRC may be influenced by patient selection factors, including clinical stability.
Sotorasib Combo Improves Patient-Reported Outcomes in KRAS G12C+ CRC
Data suggest that sotorasib plus panitumumab may represent a valuable new treatment option in this KRAS G12C-mutated colorectal cancer population.
Collaboration Brings “Excitement” to Novel Cancer Therapy Development
Geraldine O’Sullivan Coyne, MD, MRCPI, PhD, described the excitement of seeing novel molecules like antibody drug conjugates become more prominent.
Chemoimmunotherapy Less Safe, Efficacious in Younger ES-SCLC Population
Results from a retrospective study showed that chemoimmunotherapy did not prolong survival vs chemotherapy in a younger ES-SCLC population.
Adagrasib Boosts PFS, Responses vs Docetaxel in KRAS G12C+ NSCLC
Findings from the KRYSTAL-12 trial support adagrasib as a treatment option for those with disease progression on prior chemotherapy and immunotherapy.
Investigating Prolonged Perioperative Opioid Use in Surgical Oncology
Ronald Bleday, MD, credits a chronic pain clinic for consulting patients who may be at a greater risk for prolonged opioid use following surgery.
TAR-200 Appears Highly Efficacious, Safe in BCG-Unresponsive NMIBC
Results from the SunRISe-1 trial showed that TAR-200 monotherapy achieved a complete response rate of 82.4% in patients with BCG-unresponsive NMIBC.
Health Canada Approves Pembrolizumab/Surgery in Locally Advanced HNSCC
Results from the phase 3 KEYNOTE-689 trial supported the agency’s approval of the pembrolizumab/surgery regimen in PD-L1–positive head and neck cancer.
Safety Review Committee Supports CX-2051 Trial Continuation in Solid Tumors
An update of phase 1 data from the CTMX-2051-101 study is expected to be available by the first quarter of 2026.
EPCORE FL-1 Results Show Significance of Epcoritamab Combo in Follicular Lymphoma
The primary end points of the EPCORE FL-1 trial were met while assessing an epcoritamab-based combination for patients with R/R follicular lymphoma.
Anlotinib/Irinotecan Shows Promise, Durable Responses in ES-SCLC
Patients with extensive-stage small cell lung cancer experienced a median PFS and OS of 4.5 months and 7.2 months, respectively, with anlotinib plus irinotecan.
Episode 10: A Clinical Update on Advanced Urothelial Carcinoma After First-Line Strategies
Oncology Decoded provides the current management of metastatic bladder cancer, recent advancements in systemic therapy, patient selection, and AE mitigation.
Reshaping Breast Cancer Surgery and Minimizing Radical Treatment Approaches
Tran Ho, DO, FSSO, FACS, discussed how she found her passion in breast surgical oncology and how her mentors helped her achieve success.
New Unit Aims to Expand Trial and Therapy Options in The Community Setting
Geraldine O’Sullivan Coyne, MD, MRCPI, PhD, shares how a new position presents a “good opportunity” to improve community-based clinical trial access.
Navigating the Evolving Second-Line Landscape of Metastatic Urothelial Carcinoma
The latest in first- and second-line therapies for bladder cancer, including trial data, AE management, and the role of molecular testing, were discussed in the latest Oncology Decoded podcast.
HLD-0915 Earns FDA Fast Track Designation in Metastatic CRPC
Developers are enrolling those with metastatic castration-resistant prostate cancer on a phase 1/2 trial to assess the safety and tolerability of HLD-0915.
Optimizing Stepwise Pain Relief Management in the Perioperative GI Setting
The development of nonnarcotic pain medication after GI surgery may help relieve chronic pain without the risk of opioid dependence.
Standardizing Stepwise Perioperative Opioid Administration in CRC Care
Ronald Bleday, MD, stated that before standardizing a stepwise approach to treating surgical pain, providers might have overtreated patients with opioids.
MammaPrint Displays Predictive Utility for Chemo in HR+/HER2– Breast Cancer
FLEX study findings show that the MammaPrint Index was predictive of 5-year DRFI for endocrine therapy with or without chemotherapy in early breast cancer.
Alpelisib Combo Does Not Extend PFS in High-Grade Serous Ovarian Cancer
Additional research on novel targeted therapies may be necessary to address the unmet needs in this high-grade serous ovarian cancer population.
Novel CD19 CAR-NK Therapy Yields Responses in Waldenstrom Macroglobulinemia
The CD19 t-haNK therapy alone and in combination with rituximab achieved complete responses and no significant toxicities in 2 patients with late-stage WM.
